Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) SEC filings page provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, quarterly and annual reports, and other filings that describe material agreements, financial results, and key developments in Ultragenyx’s rare disease business.
Form 8-K filings for Ultragenyx often cover topics such as royalty purchase agreements, clinical and regulatory milestones, and financial updates. For example, the company has reported a Royalty Purchase Agreement with an OMERS investment vehicle involving a portion of future Crysvita royalty payments in the United States and Canada, including details on purchase price, royalty percentages, and caps based on multiples of the purchase price. Other 8-Ks summarize press releases announcing quarterly financial results, revenue by product, operating expenses, and net loss.
Ultragenyx also uses Form 8-K to report clinical and regulatory events, including initiation and progress of rolling Biologics License Application submissions for DTX401 in glycogen storage disease type Ia, longer-term Phase 3 data for DTX401, Breakthrough Therapy Designation for GTX-102 in Angelman syndrome, enrollment status of the Phase 3 Aspire study, and FDA communications such as a Complete Response Letter for UX111 in Sanfilippo syndrome type A. These filings outline requested chemistry, manufacturing, and controls information and the company’s plans to address regulatory feedback.
Through Stock Titan, users can review Ultragenyx’s SEC filings and benefit from AI-powered summaries that explain the significance of complex documents, including 10-K and 10-Q reports when available, as well as Form 4 insider transaction reports. Real-time updates from EDGAR combined with AI-generated insights help readers understand how material agreements, clinical data, and regulatory interactions influence Ultragenyx’s operations and capital structure in the rare and ultra-rare genetic disease space.
Ultragenyx Pharmaceutical Inc. reported positive Phase 3 Enh3ance results for DTX301, its investigational AAV8 gene therapy for ornithine transcarbamylase (OTC) deficiency. At Week 36, DTX301-treated patients showed an 18% reduction in 24-hour plasma ammonia AUC0-24 versus placebo, with ammonia levels generally maintained in the normal range.
Treated patients reduced ammonia scavenger medications by a mean 27% and increased protein intake by about 13%, while still keeping ammonia controlled. Patient-reported outcomes at Week 24 showed notably higher rates of symptom improvement with DTX301 compared to placebo. DTX301 was described as well tolerated, with most adverse events being mild to moderate hepatic reactions managed with steroids.
The trial continues to a second primary endpoint assessing reduction in treatment burden through 64 weeks, with additional data expected in the first half of 2027. Ultragenyx states that the program fits within its 2026 spending guidance and its goal of achieving profitability in 2027.
Ultragenyx Pharmaceutical Inc.’s EVP and Chief Legal Officer, Karah Herdman Parschauer, reported open-market sales of company common stock. She sold 6,018 shares on
RARE filed a Form 144 reporting a proposed sale of 3,508 shares of Common Stock (restricted stock) by an issuer-affiliated holder. The filing also lists recent dispositions by Karah Parschauer, including sales of 6,018 shares on 03/06/2026 and 8,135 shares on 03/02/2026.
RARE reported an insider sale filing under Form 144. The filing lists proposed sales of Performance Shares: 688 and Restricted Stock: 5,330, both dated
Ultragenyx Pharmaceutical Inc. officer John Richard Pinion reported stock-based compensation activity and a related tax sale. On March 1, 2026, he acquired 11,137 shares of common stock at $0.00 per share through the conversion of previously granted performance stock units after certification of performance metrics.
On March 2, 2026, he sold 10,029 common shares in an open-market transaction at a weighted average price of $22.80 per share, in multiple trades between $22.54 and $23.11, to pay required tax withholdings tied to RSU vesting. Following these transactions, he directly owned 110,026 common shares, including 490 shares from the employee stock purchase plan and shares underlying RSUs subject to vesting conditions.
Ultragenyx Pharmaceutical EVP & Chief Commercial Officer Erik Harris reported both an equity award and a related share sale. On March 1, 2026, he acquired 11,643 shares of common stock at $0.00 per share from previously granted performance stock units that converted upon certification of performance metrics.
On March 2, 2026, he sold 10,539 shares of common stock at a weighted-average price of $22.80 per share to cover required tax withholdings tied to restricted stock unit vesting. After these transactions, he directly held 89,515 shares of common stock, plus additional RSUs subject to vesting conditions.
Ultragenyx Pharmaceutical President & CEO Emil Kakkis reported equity compensation activity and a related tax sale. On March 1, 2026, previously granted performance stock units converted into 71,177 shares of common stock upon certification of performance metrics. On March 2, 2026, he sold 54,404 shares of common stock at a weighted average price of $22.80 per share to cover required tax withholdings from RSU vesting. After these transactions, he directly owned 658,994 shares and indirectly held 2,158,985 shares through the Emil Kakkis and Jenny Soriano Living Trust.
Ultragenyx Pharmaceutical EVP and Chief Legal Officer Karah Herdman Parschauer reported both a stock grant and a related share sale. On March 1, 2026, she acquired 11,137 shares of common stock at no cost through conversion of previously granted performance stock units upon certification of performance metrics. On March 2, 2026, she sold 8,135 shares of common stock in an open-market transaction at a weighted average price of $22.80 per share, in multiple trades between $22.54 and $23.11, to cover required tax withholdings due to vesting of restricted stock units. After these transactions, she directly held 76,346 shares, including shares acquired under the company’s employee stock purchase plan and shares underlying unvested restricted stock units subject to vesting conditions.
Ultragenyx Pharmaceutical Inc. senior vice president and chief accounting officer Theodore Alan Huizenga reported two common stock transactions. He completed an open-market sale of 1,632 shares at a weighted average price of
In a related move, he also disposed of 148 shares at
Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported a mix of stock awards and sales. On March 1, 2026, he acquired 6,143 shares of common stock at no cost when previously granted performance stock units converted after the performance metric was certified. On March 2–3, 2026, he sold a total of 10,044 shares in open-market transactions at prices around the low‑$20s per share, with some shares sold to cover required tax withholdings from restricted stock unit vesting. After these transactions, he directly owned 85,034 shares of Ultragenyx common stock.